Axsome Therapeutics
AXSM · Nasdaq · United States
Share price · AXSM
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when AXSM's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 11 Nov 2026+5.9%
Nothing announced by AXSM that day or the session before.
- 10 Nov 2026+5.2%
Nothing announced by AXSM that day or the session before.
- 23 Oct 2026-7.1%
Nothing announced by AXSM that day or the session before.
- 11 Sep 2026+4.6%
Nothing announced by AXSM that day or the session before.
- 4 May 2026+8.3%
- 30 Apr 2026+12.9%
- 31 Dec 2025+22.8%
Share of unusual movement by asset
For each asset, the share of AXSM's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(6 total)
| Target & Modality | |||
|---|---|---|---|
Dextromethorphan/bupropion(Auvelity) | Approved | sigma-1/NMDA · Dopamine/norepinephrine transporterSmall molecule | Major Depressive DisorderAlzheimer's Disease Alzheimer's Disease Agitation |
| Approved | 5-HT1B/1D receptor · Nonsteroidal Anti-inflammatory DrugSmall molecule | Migraine | |
Solriamfetol(Sunosi) | Approved | Dopamine/norepinephrine transporterSmall molecule | Major Depressive DisorderNarcolepsyAttention Deficit Hyperactivity Disorder |
| Phase 3 | norepinephrine transporterSmall molecule | Fibromyalgia | |
| Phase 3 | norepinephrine transporterSmall molecule | Narcolepsy | |
Balipodect (TAK-063)No recent activity | Phase 2 | Phosphodiesterase 10A (PDE10A)Small molecule | Schizophrenia |
Upcoming events
(10 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (2)
2027 (3)
2028 (5)
March 2028 (1)
What to watch
May 2028 (1)
What to watch
June 2028 (2)
December 2028 (1)
What to watch
Regulatory and conference events
(8)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $260M | $51M | $314M | $13M-$9.5M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $218M | $46M | $320M | $51M-$33M operating cash flow | report ↗ |
| 2026-Q1 | $191M | $53M | $305M | $65M-$21M operating cash flow | report ↗ |
| 2025-Q3 | $171M | $40M | $325M | $47M$1.1M operating cash flow | report ↗ |
| 2025-Q2 | $150M | $50M | $303M | $48M-$32M operating cash flow | report ↗ |
| 2025-Q1 | $121M | $45M | $301M | $59M-$43M operating cash flow | report ↗ |
| 2024-Q3 | $105M | $45M | $327M | $65M-$19M operating cash flow | report ↗ |
| 2024-Q2 | $87M | $50M | $316M | $79M-$30M operating cash flow | report ↗ |
| 2024-Q1 | $75M | $37M | $331M | $68M-$53M operating cash flow | report ↗ |
| 2023-Q3 | $58M | $29M | $417M | $62M-$54M operating cash flow | report ↗ |
| 2023-Q2 | $47M | $21M | $437M | $67M-$55M operating cash flow | report ↗ |
| 2023-Q1 | $95M | $18M | $247M | $11M-$5.8M operating cash flow | report ↗ |
| 2022-Q3 | $17M | $15M | $228M | $45M-$23M operating cash flow | report ↗ |
| 2022-Q2 | $8.8M | $16M | $73M | $41M-$34M operating cash flow | report ↗ |
| 2022-Q1 | — | $13M | $85M | $40M-$33M operating cash flow | report ↗ |
| 2021-Q3 | — | $13M | $115M | $35M-$27M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $639M | $183M | $323M | $46M-$93M operating cash flow | report ↗ |
Axsome reported 2025 full-year revenue of $638.5M, up 65.5% YoY, with R&D spend of $183.28M, down 2.0% YoY. The company held $322.93M in cash and equivalents and recorded a net loss of $183.17M, or $3.68 per share.
Management said current cash is sufficient to fund operations into cash flow positivity. Regulatory and clinical highlights include a Priority Review sNDA for AXS-05 in Alzheimer's disease agitation with a PDUFA date of April 30, 2026, the acquisition of AXS-17, and an on-track NDA submission for AXS-12 in narcolepsy. Axsome also resolved SUNOSI patent litigation with Alkem Laboratories and plans multiple Phase 3 trial initiations across solriamfetol and AXS-05 in 2026.
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 30 sales ($112.5M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-09-03 | Jacobson Mark L. · Chief Operating Officer | Option exercise | 10,000 | $12.95 | $130K | Form 4 |
| 2026-09-03 | Jacobson Mark L. · Chief Operating Officer | Open-market sale | 10,000 | $208.65 | $2.1M | Form 4 |
| 2026-09-03 | Jacobson Mark L. · Chief Operating Officer | Option exercise (derivative) | 10,000 | — | — | Form 4 |
| 2026-08-06 | TABUTEAU HERRIOT · director, Chief Executive Officer, 10% owner | Option exercise | 4,660 | $4.95 | $23K | Form 4 |
| 2026-08-06 | TABUTEAU HERRIOT · director, Chief Executive Officer, 10% owner | Open-market sale | 4,660 | $213.95 | $997K | Form 4 |
| 2026-08-06 | TABUTEAU HERRIOT · director, Chief Executive Officer, 10% owner | Option exercise (derivative) | 4,660 | — | — | Form 4 |
| 2026-08-05 | TABUTEAU HERRIOT · director, Chief Executive Officer, 10% owner | Option exercise | 45,004 | $4.95 | $223K | Form 4 |
| 2026-08-05 | TABUTEAU HERRIOT · director, Chief Executive Officer, 10% owner | Open-market sale | 45,004 | $212.01 | $9.5M | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 405 reporting institutions held 37.9M shares ($6.1B, 72.0% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 3,912,844 | $661.3M |
| 2 | VANGUARD PORTFOLIO MANAGEMENT LLC | 2,058,170 | $347.9M |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 1,937,752 | $327.5M |
| 4 | FMR LLC | 1,566,995 | $264.9M |
| 5 | Invesco Ltd. | 1,297,678 | $219.3M |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 1,162,981 | $196.6M |
| 7 | WELLINGTON MANAGEMENT GROUP LLP | 1,145,306 | $193.6M |
| 8 | Deep Track Capital, LP | 1,100,000 | $185.9M |
| 9 | STATE STREET CORP | 986,809 | $166.8M |
| 10 | Assenagon Asset Management S.A. | 865,958 | $146.4M |
| 11 | NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 812,809 | $137.4M |
| 12 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 737,578 | $124.7M |
| 13 | ALETHEA CAPITAL MANAGEMENT, LLC | 649,114 | $109.7M |
| 14 | D. E. Shaw & Co., Inc. | 603,465 | $102.0M |
| 15 | BANK OF AMERICA CORP /DE/ | 598,091 | $101.1M |